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Background: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian
carcinoma to evaluate the efficacy and safety of motolimod—a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate
immune responses—combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic
cell death.
Patients and methods: Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1
to receive PLD in combination with blinded motolimod or placebo. Randomization was stratified by platinum-free interval
(6 versus>6–12 months) and Gynecologic Oncology Group (GOG) performance status (0 versus 1). Treatment cycles were
repeated every 28 days until disease progression.
Results: The addition of motolimod to PLD did not significantly improve overall survival (OS; log rank one-sided P¼ 0.923,
HR¼ 1.22) or progression-free survival (PFS; log rank one-sided P¼ 0.943, HR¼ 1.21). The combination was well tolerated, with
no synergistic or unexpected serious toxicity. Most patients experienced adverse events of fatigue, anemia, nausea, decreased
white blood cells, and constipation. In pre-specified subgroup analyses, motolimod-treated patients who experienced injec-
tion site reactions (ISR) had a lower risk of death compared with those who did not experience ISR. Additionally, pre-treatment
in vitro responses of immune biomarkers to TLR8 stimulation predicted OS outcomes in patients receiving motolimod on
study. Immune score (tumor infiltrating lymphocytes; TIL), TLR8 single-nucleotide polymorphisms, mutational status in BRCA
and other DNA repair genes, and autoantibody biomarkers did not correlate with OS or PFS.
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Conclusions: The addition of motolimod to PLD did not improve clinical outcomes compared with placebo. However, subset
analyses identified statistically significant differences in the OS of motolimod-treated patients on the basis of ISR and in vitro
immune responses. Collectively, these data may provide important clues for identifying patients for treatment with immuno-
modulatory agents in novel combinations and/or delivery approaches.
Trial registration: Clinicaltrials.gov, NCT 01666444.
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Introduction
Ovarian cancer is the fifth leading cause of cancer death in
women in the United States and has the highest mortality rate of
all gynecologic cancers [1, 2]. The standard treatment of ovarian
carcinoma involves debulking surgery and combination chemo-
therapy with paclitaxel and either carboplatin or cisplatin [3].
However, despite aggressive frontline treatment, 70% of pa-
tients will relapse in the first 3 years. Among the accepted options
for patients with relapsed disease are pegylated liposomal doxo-
rubicin (PLD) and other drugs [4–8] with response rates from
10% to 25%. With a dose schedule and toxicity profile somewhat
more favorable, PLD has become a common first option for pa-
tients who relapse after platinum-based treatment [9, 10].
Numerous studies show that cell-mediated immune mechanisms
play a key role in controlling the natural history of ovarian carcin-
oma [11, 12]. PLD is an immunomodulatory agent that augments
anti-tumor immune responses, in part via killing tumor cells in a
manner that enhances uptake of tumor antigens by myeloid den-
dritic cells (mDCs), promoting antigen processing, cross-priming,
and presentation to T cells [13–15]. Despite these immune-
activating processes, tumor-infiltratingmDCsmay not become acti-
vated due to immunosuppressive factors within the local tumor
microenvironment (TME) [16]. Agents with the potential to en-
hance the immunomodulatory effects of PLD are therefore attractive
candidates for evaluation in ovarian carcinoma.
Toll-like receptors (TLRs) comprise a family of 13 pattern
recognition receptors expressed broadly on hematopoietic and non-
hematopoietic cells [17]. TLR8 is localized in endosomal compart-
ments ofmonocytes andmDC and its activation stimulates the release
of inflammatorymediators, including T cell helper 1 (Th1)-polarizing
cytokines [18, 19]. Motolimod (previously identified as VTX-2337) is
a synthetic, small molecule, selective agonist of TLR8 comprising a 2-
aminobenzazepine core [20, 21]. Motolimod stimulates natural killer
(NK) cell activity [21], augments antibody-dependent cellular cyto-
toxicity [18, 22] and induces production of IFN-c.
Because TLR8 engagement drives the maturation of mDCs and
could facilitate the development of innate and adaptive antitumor
immune response, it was hypothesized that motolimod would be
an optimal partner for PLD. Based on this hypothesis, as well as pre-
clinical and initial clinical data supporting the combination [20],
the current phase 2, randomized, placebo-controlled trial was initi-
ated to compare the efficacy and safety of motolimod plus PLD ver-
sus placebo plus PLD inwomenwith advanced ovarian carcinoma.
Methods
This phase 2, double-blind, placebo-controlled study was conducted at 105
study centers in the United States. Patients were randomized in a 1 : 1 ratio to
receive PLD 40mg/m2 i.v. on day 1 of a 28-day cycle plus motolimod 3.0mg/
m2 or placebo given SC on days 3, 10, and 17. Starting with cycle 5, dosing
consisted of 40mg/m2 PLD on day 1 plus 3.0mg/m2 motolimod or placebo
on day 3 of a 28-day cycle. Randomization was stratified by platinum-free
interval (PFI) (6 months versus>6–12 months) and GOG performance sta-
tus (0 versus 1). Treatment cycles were repeated every 28 days until progres-
sive disease (PD).
Eligible patients were 18 years and had measurable, confirmed epithelial
ovarian, fallopian tube, or primary peritoneal carcinoma that was persistent
or recurrent despite primary therapy. Recurrence must have occurred <12
months after completing platinum-based first- or second-line therapy. Up to
2 prior cytotoxic regimens were permitted; prior treatment with motolimod,
PLD, or any other anthracycline was not allowed.
Disease response was evaluated using magnetic resonance imaging or com-
puted tomography scans carried out at baseline, week 12, and every 8 weeks
thereafter until PD or the patient was put on non-protocol therapy. Tumor re-
sponses were assessed by the investigator using the Immune Related Response
Evaluation Criteria in Solid Tumors (irRECIST) [23].
Safety assessments included the surveillance and recording of adverse
events (AEs) that were graded and classified using the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE),
Version 4.0 [24].
Details on statistical methods and translational endpoints are provided in
the supplementary material, available atAnnals of Oncology online.
Results
Patient characteristics
A total of 297 patients were randomized between October 2012
and April 2014. The treatment arms were well-balanced regarding
demographics and disease characteristics (see Table 1). Of the
297 randomized patients, 294 received blinded study treatment;
147 received motolimod and 147 received placebo. The median
number of treatment doses (12 for motolimod, 13 for placebo)
and cycles (5 for both motolimod and placebo) was comparable
between the arms. The median number of PLD doses was 5
(range: 1–35) in each arm.
OS, irPFS, and ORR
The addition of motolimod to PLD did not improve either OS or
progression-free survival as assessed by irRECIST (irPFS). In the
intent-to-treat analysis, the median OS for patients in the motoli-
mod plus PLD arm was 18.1 months versus 18.9 months for pa-
tients in the placebo plus PLD arm [hazard ratio (HR) 1.22,
P¼ 0.923; Figure 1A]. The median irPFS for patients who
received motolimod plus PLD was 4.8 months versus 5.2 months
for patients in the placebo plus PLD arm placebo (HR 1.21,
P¼ 0.943; Figure 1B). (All P-values are one-sided log rank.)
Motolimod did not improve OS or irPFS in patients with PFI6
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months or >6–12 months, nor the objective response rate
(see supplementary material, available at Annals of Oncology
online).
OS and ISR
The most common motolimod-associated AE was ISR, which
occurred in 108 patients (73.5%). Planned analyses (for statistical
methods, see supplementary material, available at Annals of
Oncology online) of the association between OS and ISR sug-
gested that patients in the motolimod arm who experienced ISR
(n¼ 103) had longer OS (19.8 months) compared with motoli-
mod-treated patients who did not experience ISR (n¼ 44; 13.3
months) (Figure 1C). Using a time-dependent proportional haz-
ards model, the estimated hazard of death for ISRþ patients was
66.4% the hazard of those who were ISR (P¼ 0.067).
Safety
Motolimod plus PLD was generally safe and well-tolerated, with-
out evidence of toxicity interactions. Notable treatment-
emergent AEs (TEAEs) that were reported in a higher proportion
of patients in the motolimod arm versus placebo (10% differ-
ence) were fatigue, vomiting, ISR, chills, fever, limb edema, influ-
enza-like symptoms, and cytokine release syndrome (see
Table 2). With these exceptions, the incidence of TEAEs did not
appear to be different between the treatment arms.
Serious AEs (SAEs) were reported for 120 patients (40.8%): 60
patients (40.8%) in each treatment arm (see Table 2). Of the
SAEs that resulted in death (n¼ 13; 4.4%), 1 event—sepsis in a
patient in the placebo arm—was considered related to study
treatment. Most deaths (66%) were reported after completion of
treatment and were related to progression of underlying disease
(70.4%).
Table 1. Baseline demographics and clinical characteristics
PLD 1 placebo PLD1motolimod Total
N 5 149 (%) N5 149 (%) N5 297 (%)
Median (range) age, years 61.6 (29.7–91.1) 63.5 (39.6–84.8) 62.7 (29.7–91.1)
Race, n (%)
White 141 (94.6) 137 (92.6) 278 (93.6)
Black or African American 4 (2.7) 6 (4.1) 10 (3.4)
Asian 3 (2.0) 3 (2.0) 6 (2.0)
American Indian/Alaska Native 1 (0.7) 1 (0.7) 2 (0.7)
Not stated 0 (0.0) 1 (0.7) 1 (0.3)
Ethnicity, n (%)
Hispanic or Latino 4 (2.7) 3 (2.0) 7 (2.4)
Not Hispanic or Latino 143 (96.0) 145 (98.0) 288 (97.0)
Not stated 2 (1.3) 0 (0.0) 2 (0.7)
Histologic cell type, n (%)
Serous adenocarcinoma 122 (81.9) 124 (83.8) 246 (82.8)
Adenocarcinoma, unspeciﬁed 10 (6.7) 11 (7.4) 21 (7.1)
Endometrioid adenocarcinoma 9 (6.0) 5 (3.4) 14 (4.7)
Clear cell carcinoma 3 (2.0) 2 (1.4) 5 (1.7)
Mixed epithelial carcinoma 3 (2.0) 2 (1.4) 5 (1.7)
Undifferentiated carcinoma 1 (0.7) 3 (2.0) 4 (1.3)
Transitional cell carcinoma 1 (0.7) 1 (0.7) 2 (0.7)
GOG performance status, n (%)a
0 104 (69.8) 105 (70.9) 209 (70.4)
1 45 (30.2) 43 (29.1) 88 (29.6)
Primary tumor site, n (%)
Ovarian 119 (79.9) 116 (78.4) 235 (79.1)
Fallopian tube 12 (8.1) 13 (8.8) 25 (8.4)
Primary peritoneal 18 (12.1) 19 (12.8) 37 (12.5)
Median (range) time from diagnosis to study entry, weeks 73.1 (16.3, 948.4) 74.3 (29.3, 787.4) 73.6 (16.3, 948.4)
Prior chemotherapy regimens, n (%)
1 81 (54.4) 69 (46.6) 150 (50.5)
2 64 (43.0) 74 (50.0) 138 (46.5)
3 4 (2.7) 5 (3.4) 9 (3.0)
Platinum-free interval, n (%)a
 6 months 77 (51.7) 75 (50.7) 152 (51.2)
> 6 to 12 months 72 (48.3) 73 (49.3) 145 (48.8)
aAs randomized.
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Figure 1. Kaplan–Meier plots of OS (A) and PFS (B) in the ITT population. No signiﬁcant increase in either OS or PFS was observed between patients treated with motolimod plus PLD
(blue line) and patients treated with placebo plus PLD (red line). Landmark analysis of OS in patients receiving motolimod, comparing those who experienced injection site reaction (ISRþ;
blue line) to those who did not (ISR; red line) (C). Among motolimod-treated patients, those who were ISRþ had longer OS compared with those who were ISR.
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Correlative studies
Analysis of previous nonclinical and clinical data identified a
panel of cytokines and chemokines induced by motolimod in
human peripheral blood mononuclear cells in vitro and/or that
were upregulated in plasma following subcutaneous dosing (see
supplementary material, available at Annals of Oncology online).
In vivo analytes were quantified in plasma samples collected from
patients before and 8 h following motolimod dosing. Post-dose
levels of responsive mediators in patients treated with motolimod
plus PLD showed statistically significant increases consistent with
previous findings in human volunteers and cancer patients who
received motolimod monotherapy [18, 19] and ovarian cancer
patients treated with motolimod plus PLD [20] (Figure 2A and B;
supplementary Table S3, available at Annals of Oncology online).
In vivo responses were not significantly associated with longer OS
or irPFS (data not shown).
Before initiating study treatment, all patients were assessed for
their ability to respond to TLR8 stimulation in vitro. The repertoire
and magnitude of mediators that were significantly induced was
consistent with prior studies (Figure 3A). For all subjects, in vitro
responses in select analytes were discretized into tertiles (low, me-
dium, or high), and used to compare clinical outcomes. Subjects
with higher baseline IFN-c, TNF-a, or IL-12p40 responses who
subsequently received treatment with motolimod plus PLD had
significantly longer survival compared with motolimod-treated
subjects with low mediator response (Figure 3B). This finding was
not duplicated in the PLD plus placebo group. Additionally, ex-
ploratory analyses identified in vitro analytes that were correlated
with injection-site reactions (supplementary Figure S1, available at
Annals of Oncology online).
No significant associations were identified between OS or
irPFS and immune score (TILs), TLR8 single nucleotide poly-
morphisms (SNPs), germline BRCA–Fanconi anemia mutational
status, or autoantibody biomarkers (see supplementary material,
available at Annals of Oncology online).
Discussion
In this study of 297 patients with recurrent ovarian cancer, the
addition of motolimod to PLD did not produce an improvement
in either of the co-primary endpoints of OS or irPFS. In addition,
no statistically significant improvement in OS or PFS was
observed in any subgroup analyzed, including the subgroups
defined by PFI. The combination of motolimod plus PLD was
well tolerated and was associated with a safety profile consistent
with that seen in previous motolimod studies.
Despite the supportive preclinical data and the confirmation of
expected motolimod immunopharmacology, there was a lack of
synergy betweenmotolimod and PLD in this study. There is robust
evidence that host anti-tumor cell-mediated immune mechanisms
Table 2. Adverse events
Patients with adverse events, n (%) PLD 1 placebo
N 5 147 (%)
PLD 1motolimod
N 5 147 (%)
Total
N 5 294 (%)
Any treatment-emergent adverse event 146 (99.3) 147 (100.0) 293 (99.6)
Grade 3 91 (61.9) 94 (63.9) 185 (62.9)
Grade 4 14 (9.5) 10 (6.8) 24 (8.2)
Grade 5 6 (4.1) 7 (4.8) 13 (4.4)
Any serious adverse event 60 (40.8) 60 (40.8) 120 (40.8)
Any adverse event leading to treatment discontinuation 5 (3.4) 12 (8.2) 17 (5.8)
Treatment-emergent adverse events with 5% difference
in incidence between arms
Fatigue 109 (74.1) 129 (87.8) 238 (81.0)
Injection site reaction 13 (8.8) 108 (73.5) 121 (41.2)
Chills 25 (17.0) 93 (63.3) 118 (40.1)
Vomiting 49 (33.3) 74 (50.3) 123 (41.8)
Fever 19 (12.9) 70 (47.6) 89 (30.3)
Inﬂuenza-like symptoms 8 (5.4) 45 (30.6) 53 (18.0)
Edema limbs 19 (12.9) 37 (25.2) 56 (19.0)
Anxiety 24 (16.3) 32 (21.8) 56 (19.0)
Insomnia 16 (10.9) 27 (18.4) 43 (14.6)
Weight loss 19 (12.9) 25 (17.0) 44 (15.0)
Cytokine release syndrome 2 (1.4) 24 (16.3) 26 (8.8)
Dizziness 14 (9.5) 24 (16.3) 38 (12.9)
Muscular weakness 14 (9.5) 22 (15.0) 36 (12.2)
Dyspepsia 13 (8.8) 22 (15.0) 35 (11.9)
Hyperglycemia 28 (19.0) 19 (12.9) 47 (16.0)
Skin infection 6 (4.1) 16 (10.9) 22 (7.5)
Hypokalemia 29 (19.7) 12 (8.2) 41 (13.9)
Ascites 17 (11.6) 9 (6.1) 26 (8.8)
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play a role in the natural history of ovarian carcinoma [11, 25].
However, the disease has thus far been relatively resistant to treat-
ment with immunotherapy agents, including immune checkpoint
blockade [26, 27]. The low response rates to blockade of pro-
grammed cell death 1 (PD-1) compared with other tumor types
may be attributable at least in part to the lower rate of mutations in
ovarian cancer relative to cancers such asmelanoma or lung cancer
[28] and to a more immunosuppressive TME. This incomplete
understanding of the immunobiology of ovarian cancer renders
clinical trials in unselected patients particularly challenging, and
provides a strong impetus for better understanding of the mechan-
isms of immune suppression in ovarian cancer.
This study may provide important insights regarding immu-
nomodulatory approaches to ovarian cancer. Based on preclinical
data [20], our underlying hypothesis was that TLR8 stimulation
would activate intratumoral antigen-presenting cells, allowing
them to mobilize adaptive immunity against tumors, and also ac-
tivate intratumoral macrophages to synergistically kill tumor cells
in combination with PLD. Motolimod indeed activated innate
immunity in this study, as evidenced by the marked increase of
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Figure 2. (A) Statistically signiﬁcant (two-sided P< 0.05) upregulation of plasma analytes following subcutaneous administration of 3.0 mg/m2 of motolimod. Analytes that were pro-
spectively identiﬁed as being responsive to TLR8 stimulation by motolimod are identiﬁed with a dark gray heading. Data shown represent log-fold changes (pre-dose to 8 h post-dose) in each
analyte. P-values for each analyte are provided in supplementary Table S3, available at Annals of Oncology online. (B) In vivo upregulation of immunologically important analytes. P-values for
each analyte are provided in supplementary Table S4, available at Annals of Oncology online.
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inflammatory cytokines and chemokines in plasma after dosing
including IL-1b, IL-6, and TNFa, as well as proangiogenic factors
such as IL-8, VEGF, and MMP9. These multifaceted biologic ef-
fects highlight the complexity of systemic TLR8 activation. The
lack of correlation between the pharmacodynamic response to
motolimod and clinical outcomes further underscores this issue.
The fact that these biomarkers were assessed in vivo at a single,
operationally feasible time-point may have inherently limited
their utility to predict or correlate with clinical outcomes.
Nevertheless, in contrast to the in vivo pharmacodynamic re-
sults, a statistically significant difference was observed in the OS
of motolimod-treated patients with high baseline IFN-c, TNF-a,
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Figure 3. (A) Statistically signiﬁcant (two-sided P< 0.05) upregulation of analytes in vitro from baseline (pre-treatment) assessment of immune responsiveness to TLR8 stimulation. Data
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or IL-12p40 in vitro responses to motolimod compared with
motolimod-treated patients with low baseline analyte responses.
These data underscore the heterogeneity of immune responses,
and validate the use of pre-treatment in vitromethods for assessing
immune fitness and/or the immune response profile before initi-
ation of immunotherapy. We did not observe any correlation of
survival or benefit from the combination with BRCA-Fanconi
pathway mutation status, which may be explained by the fact that
this trial selected for BRCA mutation carrier patients with
decreased platinum sensitivity. Furthermore, pre-existing TILs did
not predict OS or benefit from the combination in this study. It is
possible that the immunomodulatory effects of PLD [13–15] may
have converted TIL-negative to TIL-positive tumors post therapy,
therebymasking the predictive effects of pre-treatment TILs.
Interestingly, patients who developed inflammatory responses
at the site of motolimod injection also had longer survival com-
pared with motolimod-treated patients who did not. It is possible
that in these ISRþ patients, motolimod led to beneficial immu-
nomodulation within the TME, resulting in improved survival in
response to therapy compared with their ISR- counterparts. ISR
may therefore represent a proxy for immune activation within
the TME. It is also likely that multiple steps of immune activa-
tion, culminating in an integrated and sustained immune re-
sponse within the TME, are required to achieve clinical benefit
following systemic administration of motolimod. As such, intra-
tumoral delivery of TLR8 agonists may be an effective approach
to more directly modulate the TME.
Collectively, the data obtained in the current study may pro-
vide important clues regarding patient selection for treatment
with TLR8 agonists, as well as new insights for modified delivery
approaches in this patient population which could be considered
for future studies.
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